Gene sequencing company Illumina sells cancer test developer – The New York Times
Illumina, the leading maker of gene sequencing machines, said Sunday it would sell Grail, a cancer test developer it bought for $7.1 billion in 2021. The move came two days after Illumina lost its case in a federal appeals court that largely upheld a Federal Trade Commission decision that Illumina should terminate its contract with … [Read more…]